Composition of Certain Financial Statement Captions (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended			3 Months Ended
	Mar. 31, 2014		Aug. 29, 2013 OPKO Biologics [Member]	Mar. 31, 2014 Pharmaceutical [Member] CURNA [Member]	Mar. 31, 2014 Pharmaceutical [Member] Exakta Opko [Member]	Mar. 31, 2014 Pharmaceutical [Member] OPKO Chile [Member]	Mar. 31, 2014 Pharmaceutical [Member] Farmadiet [Member]	Mar. 31, 2014 Pharmaceutical [Member] FineTech [Member]	Mar. 31, 2014 Pharmaceutical [Member] Sci Gen [Member]	Mar. 31, 2014 Pharmaceutical [Member] Cytochroma [Member]	Mar. 31, 2014 Pharmaceutical [Member] OPKO Biologics [Member]	Mar. 31, 2014 Diagnostics [Member] Claros [Member]	Mar. 31, 2014 Diagnostics [Member] Opko Diagnostics [Member]
Goodwill [Roll Forward]
Beginning balance	$ 226,373	[1]	$ 139,784	$ 4,827	$ 113	$ 6,102	$ 9,075	$ 11,698	$ 1,740	$ 2,069	$ 139,784	$ 17,977	$ 32,988
Acquisitions	0			0	0	0	0	0	0	0	0	0	0
Foreign exchange, other	(311)			0	0	(294)	(9)	0	(8)	0	0	0	0
Ending balance	$ 226,062	[1]	$ 139,784	$ 4,827	$ 113	$ 5,808	$ 9,066	$ 11,698	$ 1,732	$ 2,069	$ 139,784	$ 17,977	$ 32,988

[1] As of March 31, 2014 and December 31, 2013, total assets include $6.8 million and $6.7 million, respectively, and total liabilities include $11.4 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.